



OncoLegacy Journal

DRUG CONJUGATES

Cancer Research Society

“THE SMART BOMBS OF CANCER TREATMENT”

An in-depth look at how antibody-drug conjugates fuse targeting and toxicity to deliver chemotherapy directly into cancer cells.



INTRODUCTION

BY AAGRAH SINGH

Antibody-Drug Conjugates (ADCs) are an innovative class of biopharmaceuticals that may seem new and innovative, but have existed for many years. Their main purpose is to deliver high-potency treatments directly to cancer cells while protecting healthy tissue. ADCs overcome many limitations of traditional chemotherapy by using monoclonal antibodies to target specific markers on malignant cells rather than the whole body; in analogy, they work like a targeted missile.

Traditional chemotherapy works by attacking any cell in the body that divides quickly, which is the reason why it can sometimes damage the bone marrow, digestive tract, and follicles along with the tumor itself. ADCs were developed to get around the problem that traditional methods usually had. By attaching a specific, powerful cytotoxic drug to an antibody that only recognizes specific markers on cancer cells, doctors can deliver a dose of chemotherapy specifically and strongly enough that could kill a tumor cell without affecting any other parts of the body.

An ADC consists of three structural components:

- **Monoclonal antibody**
- **Cytotoxic drug** (also referred to as the payload)
- **Chemical linker**, which holds all of them together.

The chemical linker serves as a stable connection in the bloodstream, which helps prevent any premature release of the toxic drug, but eventually breaks as soon as it is inside the target site. Once the antibody binds to the target receptor on a cancer cell, it internalizes the complex through the process of endocytosis. Inside the cell itself, the ADC is transported to lysosomes, where the enzymes and acidic conditions cleave the chemical linker. Inside the cell, releasing the drug actually halts many cellular processes.

These cellular processes include disrupting microtubule assembly or damaging the DNA strands, which forces the cancer cell to undergo apoptosis, also known as programmed cell death. There are certain payloads that can pass through cellular membranes to enter neighboring cancer cells by a process known as the bystander effect.



DETECTION & MECHANISMS

ADC development presents many different scientific challenges because of the complex level of biology in tumor cells and circulation dynamics. It works by first finding the ideal tumor-associated antigens, which is a difficult process, as many markers can also be expressed at low levels in healthy tissues, which could lead to potential off-target side effects.

The important step in designing a new ADC is choosing the right antigen. Researchers have to look for markers that are expressed at high levels on cancer cells but are at very low/negligible levels on normal healthy cells. Even a small amount of overlap can cause the ADC to bind to healthy tissue, which can lead to unwanted side effects such as damage to the liver, eyes, or nervous system, depending on where that marker also happens to appear in the body. When patients receive these ADC-specific therapies, the clinicians have to closely track the circulating biomarker levels and also have to keep a record of the monitored organ function in order to measure responses and manage any potential toxicities.

Developers have to balance several factors to maximize the therapeutic efficacy:

Drug-to-Antibody Ratio (DAR): Attaching too few drug molecules reduces the treatment's potency, while attaching too many could destabilize the antibody structure, which causes it to clear from the bloodstream before it reaches the tumor.

Linker Stability: If a linker is too fragile releases toxic payloads into normal circulation, whereas an overly stable linker prevents the drug from being activated inside the cell.

Internalization Efficiency: The targeted surface antigen has to be successfully transported to the bound ADC inside the cell rather than just shedding into different extracellular spaces.

Not every antigen makes a good ADC target. Some of them stay on the cell surface once bound and never get pulled inside. Since the payload usually needs to enter the cell to work, antigens that internalize quickly are better targets than the ones that sit on the surface.



FUTURE DIRECTIONS

The field of targeted cancer therapy has grown and advanced rapidly since the early generations of ADCs entered clinical testing. Previous formulations relied only on non-specific chemical bonding, which resulted in unpredictable drug payloads and unstable linkers. Now, with these advancements, there have been breakthroughs in site-specific conjugation, which allow scientists to attach exact amounts of payload to precise amino acid locations, in order to create uniform therapies which have consistent performance.

Modern ADC platforms perform innovations that are beyond the traditional formats:

- **Bispecific ADCs:** Specifically engineered antibodies that possess dual-binding arms that lock onto two different tumor antigens
- **Novel Payload Classes:** While early ADCs used to rely only on microtubule inhibitors, newer designs have slowly started incorporating topoisomerase I inhibitors and DNA-damaging agents.
- **Immunostimulatory ADCs (ISACs):** Instead of delivering traditional chemotherapeutic toxins, ISACs carry an immune-stimulating agent into the tumor microenvironment. This triggers the patient's own immune system to recognize and attack the malignancy.

This approach represents a shift in how ADCs are being thought about. Instead of using the antibody purely as a delivery vehicle for a cell-killing poison, researchers are now exploring different ways to use the same delivery system to potentially “wake up” the immune system at the exact location where the tumor is growing. Because the immune-stimulating payload is released specifically inside the tumor rather than throughout the whole body, it can potentially trigger a strong, targeted immune response while avoiding the widespread inflammation that comes from other immune-based cancer treatments.

The trajectory of ADC development points towards increasingly intelligent therapeutics. Advances in conjugation chemistry now let researchers control exactly how many drug molecules attach and where, turning the entire conjugate into a programmable platform that can be tuned for a specific tumor, antigen, or stage of disease. As immunostimulatory, dual-payload, and degrader-antibody designs converge, ADCs are positioned not as a single drug type, but as a flexible backbone for the future of precision oncology. For a field that began with a single approved drug, that future is arriving fast.



SEVEN LAKES HS

REFERENCES

"INSPIRING THE NEXT GENERATION OF CANCER RESEARCHERS."

- Baah, S., Laws, M., & Rahman, K. M. (2021). Antibody–drug conjugates—A tutorial review. *Molecules*, 26(10), Article 2943. <https://doi.org/10.3390/molecules26102943>
- Beck, A., Goetsch, L., Dumontet, C., & Corvaia, N. (2017). Strategies and challenges for the next generation of antibody–drug conjugates. *Nature Reviews Drug Discovery*, 16(5), 315–337. <https://doi.org/10.1038/nrd.2016.268>
- Chari, R. V. J., Miller, M. L., & Widdison, W. C. (2014). Antibody–drug conjugates: An emerging concept in cancer therapy. *Angewandte Chemie International Edition*, 53(15), 3796–3827. <https://doi.org/10.1002/anie.201307628>
- Drago, J. Z., Modi, S., & Chandarlapaty, S. (2021). Antibody–drug conjugates: Coming of age in oncology. *Nature Reviews Clinical Oncology*, 18(6), 327–344. <https://doi.org/10.1038/s41571-021-00470-8>
- Dumontet, C., Reichert, J. M., Senter, P. D., Lambert, J. M., & Beck, A. (2023). Antibody–drug conjugates come of age in oncology. *Nature Reviews Drug Discovery*, 22(8), 641–661. <https://doi.org/10.1038/s41573-023-00709-2>
- Fu, Z., Li, S., Han, S., Shi, C., & Zhang, Y. (2022). Antibody drug conjugate: The "biological missile" for targeted cancer therapy. *Signal Transduction and Targeted Therapy*, 7(1), Article 93. <https://doi.org/10.1038/s41392-022-00947-7>
- Hafeez, U., Parakh, S., Gan, H. K., & Scott, A. M. (2020). Antibody–drug conjugates for cancer therapy. *Molecules*, 25(20), Article 4764. <https://doi.org/10.3390/molecules25204764>
- Khongorzul, P., Ling, C. J., Khan, F. U., Ihsan, A. U., & Zhang, J. (2020). Antibody–drug conjugates: A comprehensive review. *Molecular Cancer Research*, 18(1), 3–19. <https://doi.org/10.1158/1541-7786.MCR-19-0582>
- Opaliński, Ł., Szymczyk, J., Szczepara, M., Kucińska, M., Krowarsch, D., Zakrzewska, M., & Otlewski, J. (2018). High affinity promotes internalization of engineered antibodies targeting FGFR1. *International Journal of Molecular Sciences*, 19(5), Article 1435. <https://doi.org/10.3390/ijms19051435>
- Tonon, G., Rizzolio, F., Visentin, F., & Scattolin, T. (2024). Antibody drug conjugates for cancer therapy: From metallodrugs to nature-inspired payloads. *International Journal of Molecular Sciences*, 25(16), Article 8651. <https://doi.org/10.3390/ijms25168651>
- Tsuchikama, K., & An, Z. (2018). Antibody–drug conjugates: Recent advances in conjugation and linker chemistries. *Protein & Cell*, 9(1), 33–46. <https://doi.org/10.1007/s13238-016-0323-0>